DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

NCT05566795 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

418

Enrollment

INDUSTRY

Sponsor class

Conditions

Low-grade Glioma
Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma
Pediatric Low-grade Glioma

Interventions

DRUG: Tovorafenib
DRUG: Chemotherapeutic Agent

Sponsor

Day One Biopharmaceuticals, Inc.

Collaborators

SIOPe Brain Tumor Group LOGGIC Consortium